We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $37M
1-Year Est. Return 63.54%
This Fund
S&P 500
This Quarter Est. Return
-22.77%
1 Year Est. Return
+63.54%
3 Year Est. Return
+38.32%
5 Year Est. Return
+47.02%
10 Year Est. Return
+2,089.98%
AUM
$1.72B
AUM Growth
-$1.36B
Cap. Flow
-$888M
Cap. Flow %
-51.56%
Top 10 Hldgs %
32.97%
Holding
299
New
73
Increased
48
Reduced
40
Closed
96

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$37.8M
2
GH icon
Guardant Health
GH
+$19.9M
3
LUNG icon
Pulmonx
LUNG
+$15.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.5M
5
LYRA
LYRA THERAPEUTICS INC
LYRA
+$11.2M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$18M
2
CCCC icon
C4 Therapeutics
CCCC
+$15.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13.5M
4
ICUI icon
ICU Medical
ICUI
+$12.8M
5
CNVY
Convey Health Solutions Holdings, Inc.
CNVY
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 32.95%
2 Industrials 0.3%
3 Consumer Staples 0.27%
4 Materials 0.11%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TCDA
176
DELISTED
Tricida, Inc. Common Stock
TCDA
$483K 0.03%
49,900
-130,916
-72% -$1.25M
GBT
177
DELISTED
Global Blood Therapeutics, Inc.
GBT
$462K 0.03%
14,454
-15,000
-51% -$439K
QNCX icon
178
CALL
Quince Therapeutics
QNCX
$34M
$444K 0.03%
1,000
– –
UBX
179
CALL
DELISTED
Unity Biotechnology
UBX
$442K 0.03%
78,380
– –
KRTX
180
CALL
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$392K 0.02%
+3,100
New +$356K
ISEE
181
PUT
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$327K 0.02%
34,000
– –
RCOR
182
DELISTED
Renovacor, Inc.
RCOR
$294K 0.02%
144,925
-465
-0.3% -$1.23K
IMCR icon
183
Immunocore
IMCR
$1.74B
$239K 0.01%
+6,419
New +$208K
ZYME icon
184
Zymeworks
ZYME
$1.84B
$237K 0.01%
+44,696
New +$270K
AMLX icon
185
Amylyx Pharmaceuticals
AMLX
$2.52B
$203K 0.01%
10,550
+550
+6% +$6.53K
UBX
186
DELISTED
Unity Biotechnology
UBX
$202K 0.01%
35,909
-121,905
-77% -$1.02M
CNCE
187
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$187K 0.01%
+44,357
New +$176K
LXRX icon
188
CALL
Lexicon Pharmaceuticals
LXRX
$1.05B
$167K 0.01%
+89,900
New +$172K
SLGCW
189
DELISTED
SomaLogic, Inc. Warrant
SLGCW
$155K 0.01%
204,401
– –
UPC icon
190
Universe Pharmaceuticals Inc
UPC
$3.79M
$150K 0.01%
67
-233
-78% -$891K
TALKW
191
DELISTED
Talkspace Inc Warrant
TALKW
$149K 0.01%
427,194
– –
SVRA icon
192
Savara
SVRA
$1.09B
$144K 0.01%
95,014
– –
VINC
193
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$143K 0.01%
5,423
– –
NKTR icon
194
CALL
Nektar Therapeutics
NKTR
$2.58B
$139K 0.01%
2,440
-26,553
-92% -$1.68M
ROIVW
195
DELISTED
Roivant Sciences Ltd. Warrant
ROIVW
$120K 0.01%
199,648
– –
MTCR
196
DELISTED
Metacrine, Inc. Common Stock
MTCR
$99K 0.01%
198,230
– –
MAPSW
197
DELISTED
WM TECHNOLOGY INC WTS
MAPSW
$33K ﹤0.01%
50,000
– –
RCOR.WS
198
DELISTED
Renovacor, Inc. Warrants, entitling the holder thereof to purchase one-half (1/2) of a share of common stock at a price of $11. 50 per whole share
RCOR.WS
$8K ﹤0.01%
150,632
– –
SBIGW
199
DELISTED
SpringBig Holdings, Inc. Warrant
SBIGW
$1K ﹤0.01%
+10,000
New +$1.33K
A icon
200
PUT
Agilent Technologies
A
$42.1B
– –
-75,000
Closed -$9.93M
6 7
8
9 10

Similar funds

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
RH
Riverstone Holdings New York $36.9M AUM 80.85% 1-Year Est. Return
ICP
ION Crossover Partners Herzliya Pituach, Israel $36.9M AUM
GC
Gullane Capital Memphis, Tennessee $37.4M AUM 112.18% 1-Year Est. Return
BAM
BLKBRD Asset Management Old Greenwich, Connecticut $38.3M AUM 34.49% 1-Year Est. Return
CM
CoinFund Management New York $35.4M AUM
AP
Atairos Partners Bryn Mawr, Pennsylvania $35.2M AUM 32.88% 1-Year Est. Return
ACM
Altai Capital Management West Hollywood, California $35M AUM 28.16% 1-Year Est. Return

Pura Vida Investments's Q2 2022 Portfolio in Review

As of Q2 2022, Pura Vida Investments held 299 positions worth $1.72B, down 44% from $3.08B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Pura Vida Investments withdrew a net $888M in Q2 2022, closing 96 positions and reducing 40 holdings. Its most notable exit was C4 Therapeutics, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 24% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Pura Vida Investments opened a new position in Glaukos worth $36.2M.

  • Pura Vida Investments's largest Q2 2022 buy was Glaukos: 796,600 shares worth $36.2M.
  • Pura Vida Investments added most to Guardant Health in Q2 2022, an estimated $19.9M increase.
  • Pura Vida Investments's biggest Q2 2022 reduction was Vertex Pharmaceuticals, cutting an estimated $18M.
  • Pura Vida Investments fully exited C4 Therapeutics in Q2 2022, selling an estimated $15.2M.
  • Pura Vida Investments's ten largest holdings make up 33% of its $1.72B portfolio in Q2 2022.
  • Pura Vida Investments opened 73 new positions and closed 96 in Q2 2022.
  • Pura Vida Investments's portfolio value fell 44% quarter-over-quarter to $1.72B.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.